Erschienen in:
27.10.2016 | Portal Hypertension (K Brown, Section Editor)
Possible Treatment Strategies for Portal Hypertension in Liver Cirrhosis
verfasst von:
Robert Schierwagen, Frank Erhard Uschner, Sabine Klein, Jonel Trebicka
Erschienen in:
Current Hepatology Reports
|
Ausgabe 4/2016
Einloggen, um Zugang zu erhalten
Abstract
Purpose of the Review
Chronic liver injury leading to fibrosis and complicated by portal hypertension is an emerging burden for health systems worldwide, but current treatments are few and poorly effective. Therefore, this review aims to present diverse potential treatment approaches that are currently under investigation or on their way to clinical use.
Recent Findings
These options involve statins, the renin-angiotensin system and their downstream effectors, the anticoagulation system, farnesoid-x receptor agonism, and various other targets.
Summary
Since activated hepatic stellate cells play a pivotal role in both fibrogenesis and portal hypertension, most of these potential treatment approaches target directly or indirectly this profibrotic and procontractile cells in liver fibrosis with portal hypertension. Special focus should be paid to cell-specific treatments to minimize side effects and systemic complications in treatment of liver fibrosis and portal hypertension.